Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 139
Filter
1.
Sci Rep ; 13(1): 7044, 2023 04 29.
Article in English | MEDLINE | ID: mdl-37120662

ABSTRACT

Patients with inflammatory bowel disease (IBD) treated with biologic and/or immunosuppressant drugs are at increased risk for opportunistic infections. Seroprevalence studies can confirm the diagnosis of SARS-CoV-2 infections as well as the associated risk factors. This is a descriptive study which primary endpoints were to highlight the prevalence of SARS-CoV-2 antibodies in a cohort of IBD patients in March 2021, and to analyze seroconversion in patients with known COVID-19 infection and its relationship with IBD treatments. Patients filled in a questionnaire about symptoms of COVID-19 infection and clinical information about their IBD. All included patients were tested for SARS-CoV-2 antibodies. 392 patients were included. Among patients with clinical infection, 69 patients (17,65%) were IgG-positive, 286 (73,15%) IgG-negative and 36 (9,21%) indeterminate. In relation to seroconversion among patients under biologic treatment, 13 patients of the 23 with a previous positive CRP developed antibodies (56.5%). However, when the influence of immunosuppressive treatment on the probability of developing antibodies was analyzed, no significant differences were seen between those patients with or without treatment (77.8% vs. 77.1%, p = 0.96). In our cohort of IBD patients, after one year of pandemic, there were 18.64% IgG positive patients, a higher prevalence than the general population (15.7%).


Subject(s)
Biological Products , COVID-19 , Inflammatory Bowel Diseases , Humans , COVID-19/epidemiology , Seroepidemiologic Studies , SARS-CoV-2 , Antibodies, Viral , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/drug therapy , Inflammatory Bowel Diseases/epidemiology , Immunoglobulin G , Biological Products/therapeutic use
2.
Food Res Int ; 130: 108922, 2020 04.
Article in English | MEDLINE | ID: mdl-32156370

ABSTRACT

The aim of this study was to improve the stability and antioxidant activity of yarrow phenolic compounds upon an in vitro simulated gastrointestinal digestion. Therefore, two types of caseins-based delivery systems, sodium caseinate stabilized nanoemulsions (NEs) and glucono delta-lactone acidified milk gels (MGs), were formulated containing an ultrasound-assisted yarrow extract (YE) at two concentrations (1 and 2.5 mg/mL). Formulations with 1 mg/mL of YE were chosen based on their higher encapsulation efficiency to perform the in vitro digestion experiments. After digestion, YE-loaded NEs only partially protected phenolic compounds from degradation; meanwhile the phenolic composition of YE including in MGs after digestion was quite similar to undigested YE. Moreover, the antioxidant activity of MGs after digestion was higher than NEs digested samples, which confirms the higher protection of YE phenolic compound by the milk gels systems. This research demonstrated the potential use of acidified MGs as carriers to improve the stability and antioxidant activity of yarrow phenolic compounds. Therefore, these matrices could be employed to develop new dairy products enriched with phenolic compounds.


Subject(s)
Achillea/metabolism , Antioxidants/metabolism , Digestion , Food Handling/methods , Milk/chemistry , Phenols/metabolism , Animals , Beverages/analysis , Emulsions , Gels , Hydrogen-Ion Concentration , In Vitro Techniques , Nanotechnology
3.
J Dairy Sci ; 102(10): 8604-8613, 2019 Oct.
Article in English | MEDLINE | ID: mdl-31378502

ABSTRACT

The objective of this work was to better understand the effect of differences in milk protein composition, and specifically, a change in ß-casein to total casein in a milk-based matrix, on growth performance and metabolic and inflammatory responses using a piglet model. Three formulas were optimized for piglets, with similar metabolizable energy, total protein content, and other essential nutrients. Only the protein type and ratio varied between the treatments: the protein fraction of the control diet contained only whey proteins, whereas 2 other matrices contained a whey protein to casein ratio of 60:40, and differed in the amount of ß-casein (12.5 and 17.1% of total protein). Piglets fed formula containing whey proteins and caseins, regardless of the concentration of ß-casein, showed a significantly higher average daily gain, average daily feed intake, and feed efficiency compared with piglets consuming the formula with only whey protein. Consumption of the formula containing only whey protein showed higher levels of plasma glucagon-like peptide-1 and ghrelin compared with the consumption of formula containing casein and whey protein. A positive correlation was observed between postprandial time and glucagon-like peptide-1 response. The intestinal pro-inflammatory cytokine tumor necrosis factor α increased significantly in piglets fed the whey protein/casein diet compared with those fed whey protein formula. All formula-fed piglets showed a lower level of IL-6 cytokine compared with the ad libitum sow-fed piglets, regardless of composition. No significant differences in the anti-inflammatory IL-10 concentration were observed between treatment groups. Milk protein composition contributed to the regulation of piglets' metabolic and physiological responses, with whey protein/casein formula promoting growth performance and a different immune regulatory balance compared with a formula containing only whey protein. Results indicated no differences between treatments containing different levels of ß-casein.


Subject(s)
Animal Feed , Caseins/pharmacology , Cytokines/metabolism , Milk Proteins/pharmacology , Animals , Caseins/metabolism , Diet/veterinary , Energy Metabolism , Female , Interleukin-10/metabolism , Male , Milk/metabolism , Milk Proteins/chemistry , Milk Proteins/metabolism , Random Allocation , Swine , Whey Proteins/analysis , Whey Proteins/metabolism , Whey Proteins/pharmacology
4.
Food Funct ; 10(4): 1870-1879, 2019 Apr 17.
Article in English | MEDLINE | ID: mdl-30768115

ABSTRACT

An increasing body of evidence demonstrates that differences in protein composition in the food matrix can significantly affect its biological functionality. The present research hypothesized that a matrix containing the same level of dairy protein, but with different composition, even when showing similar properties during digestion, may have a different biological functionality. To test this hypothesis, three matrices, containing 2.8% protein and similar amounts of fat and solid were prepared, either with 100% whey proteins, or with a ratio of caseins to whey protein of 40 : 60, but differing in ß-casein ratio. The mixtures were subjected to in vitro digestion, and the digestates were used in uptake experiments using Caco-2 cell monolayers. The basolateral fraction metabolized by the cells was used to stimulate human LPS-stimulated THP-1 macrophages and the concentration of selected cytokines were measured, as an indication of potential differences in biological functionality between the different dairy matrices. All three digestates induced a significant reduction in IL-1ß cytokines, with the casein-containing treatments inducing a greater decrease compared to that containing only whey proteins. The matrix containing the highest ratio of ß-casein induced the lowest secretion of proinflammatory cytokines TNF-a and IL-6. This study demonstrated that milk protein composition does not only affect the rate of gastric proteolysis and structure of the gastric digestate, but will cause differences in physiological effects. This research stressed the role of milk protein components during digestion, and of ß-casein in particular, and their potential to modulate biological functions in the gastrointestinal tract.


Subject(s)
Anti-Inflammatory Agents/metabolism , Caseins/metabolism , Gastrointestinal Tract/metabolism , Whey Proteins/metabolism , Caco-2 Cells , Dairy Products/analysis , Digestion , Humans , Interleukin-1beta/metabolism , Interleukin-6/metabolism , Macrophages/metabolism , Models, Biological , Tumor Necrosis Factor-alpha/metabolism
5.
J Dairy Sci ; 101(4): 2851-2861, 2018 Apr.
Article in English | MEDLINE | ID: mdl-29402390

ABSTRACT

We investigated the effect of protein composition and, in particular, the presence of whey proteins or ß-casein on the digestion behavior of a model infant formula using an in vivo piglet model. Three isocaloric diets optimized for piglets were prepared with the same concentrations of protein. For protein source, 1 diet contained only whey proteins and 2 contained a casein:whey protein ratio of 40:60 but differed in the amount of ß-casein. To obtain the desired protein compositions, skim milk was microfiltered at 7 or 22°C, and retentates and permeates were combined with whey protein isolate. The diets were optimized to the nutritional needs of the piglets and fed to 24 newborn piglets for 18 d. Eight piglets were also fed ad libitum with sow milk and considered only as reference (not included in the statistical analysis). The study was carried out in 2 blocks, killing the animals 60 and 120 min after the last meal. All gastric contents, regardless of diet, showed a wide range of pH. Postprandial time did not affect the pH or physical properties of the gastric digesta. The digesta from whey protein-casein formulas showed significantly higher viscosity, a higher storage modulus, and a denser microstructure than digesta obtained from piglets fed whey protein formula. The ß-casein:total casein ratio at the level used in this study did not significantly affect the physical and chemical properties of the stomach digestate. Although caseins showed extensive gastric hydrolysis, whey proteins remained largely intact at both postprandial times. The results indicate that the presence of different concentrations of milk proteins can be critical to the digestion properties of the food matrix and may affect the nutritional properties of the components.


Subject(s)
Digestion , Gastric Mucosa/metabolism , Infant Formula/chemistry , Milk Proteins/chemistry , Milk/chemistry , Animals , Animals, Newborn , Caseins/pharmacology , Diet , Female , Food, Formulated , Hydrolysis , Swine , Viscosity , Whey Proteins/pharmacology
6.
Food Res Int ; 97: 71-77, 2017 07.
Article in English | MEDLINE | ID: mdl-28578067

ABSTRACT

The digestion, absorption, uptake and bioavailability of a rosemary supercritical fluid extract encapsulated in oil in water emulsion were studied. Two emulsions with opposite surface charge were prepared, containing 7% canola oil, and either 2% lactoferrin or whey protein isolate. When absorption and uptake of carnosic acid and carnosol were followed on Caco-2 cell monolayers, there were no differences with protein type. However, when co-cultures of HT-29 MTX were employed, the presence of mucus caused a higher retention of carnosic acid in the apical layer for lactoferrin emulsions. The immune activity of the bioavailable fractions collected from cell absorption experiments was tested ex vivo on murine splenocytes. Although transport through the intestinal barrier models was low, the bioavailable fractions showed a significant effect on splenocytes proliferation. These results demonstrated the potential of using rosemary supercritical extract through protein stabilized oil in water emulsions, as a food with immunomodulatory functionality.


Subject(s)
Emulsions/chemistry , Emulsions/pharmacokinetics , Plant Extracts/chemistry , Plant Extracts/pharmacokinetics , Rosmarinus/chemistry , Abietanes , Animals , Biological Availability , Caco-2 Cells , Female , HT29 Cells , Humans , Lactoferrin/chemistry , Mice , Mice, Inbred BALB C
7.
J Dairy Sci ; 100(6): 4213-4222, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28343627

ABSTRACT

The milk fat globule membrane (MFGM) is a unique colloidal assembly of phospholipids and proteins, with numerous potential applications as functional ingredient. The phospholipid components of the MFGM are gaining interest as they are a useful matrix for use as a constituent of delivery systems such as liposomes. Liposomes formulated with milk phospholipids are becoming an alternative to other sources of phospholipids such as soybean or egg yolk. However, incorporation of phospholipids fractionated from the milk fat globule membrane in dairy products requires an in-depth understanding of the functional properties of phospholipids. In particular, it is critical to understand which factors play a role in their stability and bioefficacy as delivery systems. Moreover, chemical and physical modifications of phospholipid liposomes occurring during digestion and the fate of the encapsulated compounds are very important to understand. This review discusses recent findings on the structure and functionality of MFGM, the bioactivity of the phospholipids fraction, their utilization as delivery systems, and their stability through gastrointestinal transit.


Subject(s)
Drug Carriers/administration & dosage , Glycolipids/chemistry , Glycoproteins/chemistry , Phospholipids/administration & dosage , Animals , Colloids , Digestion , Drug Carriers/chemistry , Drug Carriers/metabolism , Lipid Droplets , Liposomes , Phospholipids/chemistry , Phospholipids/metabolism
8.
Int J Lab Hematol ; 37(5): 686-9, 2015 Oct.
Article in English | MEDLINE | ID: mdl-25996654

ABSTRACT

IgM multiple myeloma (MM) is a rare subtype of myeloma that shares clinical and pathological features with Waldenström's macroglobulinaemia. These are two separate entities that differ both in therapy and prognosis. We report a 57-year-old male, who presented with anaemia, hypercalcaemia, acute renal failure and several vertebral fractures that clinically suggested a multiple myeloma. Further investigations revealed a serum monoclonal component of IgM lambda type and a bone marrow infiltrated by small, lymphoplasmocytic cells. IgM MM was finally diagnosed by means of both inmunophenotypic and immunohistochemistry techniques, stressing the importance of inmunophenotypic evaluation when clinical and morphological features are discordant. Fluorescence in situ hybridization (FISH) studies disclosed a particular combination of deletion 13q14, t(11;14) and monoallelic deletion C-MAF without t(14;16). The clinical evolution after a Bortezomib-containing polychemotherapy and autologous stem cell transplantation (ASCT) conditioned with busulphan and melphalan is also presented. This very uncommon case highlights the impact of immunophenotyping on the differential diagnosis between IgM MM and WM, to choose the best treatment and establish an appropriate outcome.


Subject(s)
Gene Deletion , Immunoglobulin M/blood , Multiple Myeloma/blood , Multiple Myeloma/genetics , Proto-Oncogene Proteins c-maf/genetics , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biopsy , Bone Marrow/pathology , Diagnosis, Differential , Humans , Immunophenotyping , Male , Middle Aged , Multiple Myeloma/diagnosis , Multiple Myeloma/drug therapy , Treatment Outcome , Waldenstrom Macroglobulinemia
10.
Allergol. immunopatol ; 40(1): 3-8, ene.-feb. 2012.
Article in English | IBECS | ID: ibc-96251

ABSTRACT

Background: The IL-15/NF-KappaB axis has an important role in coeliac disease (CD) and may represent a molecular target for immunomodulation. Ascorbate (vitamin C) is known to show inhibitory effects on NF-KappaB. Therefore, we studied if ascorbate supplementation to gliadin gliadin-stimulated biopsy culture could down-regulate the mucosal immune response to gliadin in CD. Methods: Duodenal biopsy explants from treated CD patients were gliadin challenged in vitro (100ìg/ml) with and without 20mM ascorbate. An extra tissue explant in basal culture was used as internal control. Secretion levels of nitrites (3h), and IFNGamma, TNFalpha, IFNalpha, IL-17, IL-13, and IL-6 (24h) were measured on the supernatants. IL-15 was assayed by western-blot on whole protein duodenal explants. Results: The addition of ascorbate to in vitro culture gliadin-challenged biopsies blocked the secretion of nitrites (p=0.013), IFNGamma (p=0.0207), TNFalpha (p=0.0099), IFNá (p=0.0375), and IL-6 (p=0.0036) compared to samples from non-ascorbate supplemented culture. Cytokine secretion was downregulated by ascorbate even to lower values than those observed in basal cultures (IFNGamma: p=0.0312; TNFalpha: p=0.0312; IFNá: p=0.0312; and IL-6: p=0.0078). Gliadin-challenge induced IL-15 production in biopsies from treated CD patients, while the addition of ascorbate to culture medium completely inhibited IL-15 production. Moreover, the inhibition of IL-15 by ascorbate took place even in the only treated CD-patient who had basal IL-15 production. Conclusions: Ascorbate decreases the mucosal inflammatory response to gluten in an intestinal biopsy culture model, so it might have a role in future supplementary therapy in CD(AU)


Subject(s)
Humans , Ascorbate Oxidase/pharmacokinetics , Immunity, Mucosal/physiology , Gliadin/pharmacokinetics , Celiac Disease/physiopathology , Inflammation/physiopathology , Interleukin-15/immunology , Ascorbic Acid/pharmacokinetics
11.
Allergol Immunopathol (Madr) ; 40(1): 3-8, 2012.
Article in English | MEDLINE | ID: mdl-21420224

ABSTRACT

BACKGROUND: The IL-15/NF-κB axis has an important role in coeliac disease (CD) and may represent a molecular target for immunomodulation. Ascorbate (vitamin C) is known to show inhibitory effects on NF-κB. Therefore, we studied if ascorbate supplementation to gliadin gliadin-stimulated biopsy culture could down-regulate the mucosal immune response to gliadin in CD. METHODS: Duodenal biopsy explants from treated CD patients were gliadin challenged in vitro (100 µg/ml) with and without 20mM ascorbate. An extra tissue explant in basal culture was used as internal control. Secretion levels of nitrites (3h), and IFNγ, TNFα, IFNα, IL-17, IL-13, and IL-6 (24h) were measured on the supernatants. IL-15 was assayed by western-blot on whole protein duodenal explants. RESULTS: The addition of ascorbate to in vitro culture gliadin-challenged biopsies blocked the secretion of nitrites (p=0.013), IFNγ (p=0.0207), TNFα (p=0.0099), IFNα (p=0.0375), and IL-6 (p=0.0036) compared to samples from non-ascorbate supplemented culture. Cytokine secretion was downregulated by ascorbate even to lower values than those observed in basal cultures (IFNγ: p=0.0312; TNFα: p=0.0312; IFNα: p=0.0312; and IL-6: p=0.0078). Gliadin-challenge induced IL-15 production in biopsies from treated CD patients, while the addition of ascorbate to culture medium completely inhibited IL-15 production. Moreover, the inhibition of IL-15 by ascorbate took place even in the only treated CD-patient who had basal IL-15 production. CONCLUSIONS: Ascorbate decreases the mucosal inflammatory response to gluten in an intestinal biopsy culture model, so it might have a role in future supplementary therapy in CD.


Subject(s)
Ascorbic Acid/pharmacology , Celiac Disease/drug therapy , Gliadin/immunology , Inflammation/prevention & control , Adult , Aged , Biopsy , Celiac Disease/immunology , Cytokines/biosynthesis , Female , Humans , Immunity, Mucosal/drug effects , Interleukin-15/antagonists & inhibitors , Interleukin-15/physiology , Male , Middle Aged
14.
Rev Esp Enferm Dig ; 102(10): 587-90, 2010 Oct.
Article in English | MEDLINE | ID: mdl-21039067

ABSTRACT

The standard treatment of chronic hepatitis C, pegylated interferon and ribavirin (pegI/R), has many limitations in both effectiveness and secondary effects, which makes it unsuitable or even contraindicated for some patients. In hepatitis C virus-infected cystic fibrosis patients this treatment could increase respiratory infections with subsequent pulmonary function deterioration. On the contrary, hepatitis C virus (HCV) infection may make lung transplant (LT) unfeasible. We present the case of a cystic fibrosis-young man diagnosed with HCV infection during LT assessment who was treated with pegI/R. In spite of the lung function worsening and respiratory infections, he managed to complete treatment and even sustained virological response (SVR). At present he is on LT waiting list.


Subject(s)
Cystic Fibrosis/complications , Cystic Fibrosis/surgery , Hepatitis C, Chronic/drug therapy , Lung Transplantation/physiology , Adult , Antiviral Agents/therapeutic use , Drug Therapy, Combination , Hepatitis C, Chronic/complications , Humans , Interferons/therapeutic use , Liver/pathology , Male , Portal System/pathology , Ribavirin/therapeutic use
16.
Rev Gastroenterol Mex ; 75(3): 253-60, 2010.
Article in Spanish | MEDLINE | ID: mdl-20959173

ABSTRACT

BACKGROUND: Gastric adenocarcinoma (GA) has been considered a disease of elderly age and has been rarely reported in patients younger than 35 years of age. The aim of thisΩ demographic, clinicopathological and prognosis of gastric cancer in young patients and to compare their features with the behavior in elder adults. METHODS: Between 1993 and 2008, 1536 patients with GA were enrolled in a retrospective database. Clinical and pathologic features of thirty patients aged 35 years or less (young group) were compared with those of 458 aged 75 years or more (elder group). RESULTS: Mean patient age was 31 and 80-years old in the young and elder groups, respectively, with a predominance of females in the last group (61%). Lauren diffuse type carcinoma was more frequent in people younger than 35 years (70%) than in older patients (17.4%). Main symptoms were dyspepsia (40%) and hemorrhage (20%). The most common T stage in young and elder patients was T3 (52.9% and 56.7% respectively). Surgical resection was performed in 68% of cases and the rest received only systemic chemotherapy. CONCLUSION: Gastric adenocarcinoma is rare in young patients and most cases presented at advanced clinical stage similar to elderly patients, so the prognosis in both age groups is poor. For this reason is important to be aware of alarm symptoms and risk factors in order to perform an early endoscopic diagnosis and a treatment with curative intent.


Subject(s)
Adenocarcinoma/epidemiology , Stomach Neoplasms/epidemiology , Adenocarcinoma/pathology , Adenocarcinoma/therapy , Adult , Age Factors , Aged , Aged, 80 and over , Combined Modality Therapy , Databases, Factual , Female , Humans , Male , Mexico/epidemiology , Middle Aged , Retrospective Studies , Stomach Neoplasms/pathology , Stomach Neoplasms/therapy , Survival Analysis , Young Adult
18.
Rev. esp. enferm. dig ; 102(10): 587-590, oct. 2010.
Article in Spanish | IBECS | ID: ibc-82200

ABSTRACT

El tratamiento estándar de la hepatitis crónica C, interferón pegilado (INF-peg) y ribavirina (RBV), puede ser inadecuado o incluso estar contraindicado en algunos pacientes debido a sus limitaciones en cuanto a eficacia y efectos adversos. En pacientes con fibrosis quística infectados por el virus de la hepatitis C (VHC) el tratamiento antiviral podría aumentar las infecciones respiratorias con el consiguiente empeoramiento de la función pulmonar. Por contra, la infección por VHC podría desestimar a estos pacientes para un necesario trasplante pulmonar. Presentamos el caso de un varón con fibrosis quística diagnosticado de infección VHC durante su evaluación previa al trasplante pulmonar. El paciente fue tratado con INF-peg y RBV. A pesar del empeoramiento en la función pulmonar y numerosas infecciones respiratorias intercurrentes, logró completar el tratamiento y obtener respuesta viral sostenida, encontrándose actualmente en lista de espera(AU)


The standard treatment of chronic hepatitis C, pegylated interferon and ribavirin (pegI/R), has many limitations in both effectiveness and secondary effects, which makes it unsuitable or even contraindicated for some patients. In hepatitis C virus-infected cystic fibrosis patients this treatment could increase respiratory infections with subsequent pulmonary function deterioration. On the contrary, hepatitis C virus (HCV) infection may make lung transplant (LT) unfeasible. We present the case of a cystic fibrosisyoung man diagnosed with HCV infection during LT assessment who was treated with pegI/R. In spite of the lung function worsening and respiratory infections, he managed to complete treatment and even sustained virological response (SVR). At present he is on LT waiting list(AU)


Subject(s)
Humans , Male , Adult , Hepatitis C, Chronic/diagnosis , Hepatitis C, Chronic/therapy , Cystic Fibrosis/complications , Cystic Fibrosis/diagnosis , Ribavirin/therapeutic use , Respiratory Tract Infections/complications , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/drug therapy , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/physiopathology , Transplantation Conditioning/instrumentation , Transplantation Conditioning/methods , Transplants/trends , Microbial Sensitivity Tests , Interferons/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL
...